Progesterone receptor

Slides:

Advertisements

Similar presentations

Supplemental Figure 1 a % pulldown from input LNCaP/scrambled-siRNA Figure 1 A, ChIP analysis of AR and PHB binding to the PSA promoter in the LNCaP/scrambled-siRNA.

Advertisements

Supplementary Figure 1 Supplemental Figure 1. Nogin siRNA potentiates BMP2-induced Smad-dependent BMP- signaling MDA-MB-231 breast cancer cells. MDA-MB-231/BREluc.

Supplemental Figure 1 A No. at risk T T T

Duong et al Figure 1 A InputsGST-Mdm2 HEGO HE11HE19HE15 HEGO HE11 HE19HE15 B HEGO A/BCEFD 1595 HE11 A/BEFD CEFD HE19 A/BC HE15 C D ER  I GST-Mdm2GST C.

Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.

Knight et al – Supplementary Table Supplemental Table 1: Cell line Densitometry AROSSIRT1 ARPE WI MCF10A HCT HCT116.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.

Figure 1. Figure 2 ab p= p= *** Figure 3 a *** b cFos TP53 Beta actin cFos TP53 Beta actin.

Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *

Supplemental Figure S1: Diagram to show previously reported interactions between EGFR and 23 other Egr1 target genes using Pathway Studio, Ariadne Inc.

Supplemental Figure S1 A B MDA-MB-231 MCF-7 BCL-2MDA-MB-231 BCL-2 MCF-7 Bcl-2 Actin Bcl-2 Actin.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

Supplementary Figure S1 a

Figure 6. Effect of Withaferin A (WA) treatment on leptin-induced signaling in breast cancer cells. A) Immunoblotting for pSTAT3 (Tyr705), total STAT3,

* Supplementary Figure 1: Treatment of siramesine with various chemotherapeutic drugs in MDA MB 231 cells. MDA MB 231 cells were treated with 10μM siramesine.

Figure 3. Synergistic effects of the combination of trabectedin and olaparib on poly(ADP-ribosyl)ation and DNA damage in four different breast cancer cell.

Supplemental Material

A Western Blot B Colony Scattering Assay VEC ARTN siCONT siARTN VEC

Figure S1. qPCR analysis of the EMT markers ZEB2 and SNAI1 in Syndecan-1 and control siRNA transfected MDA-MB-231 and MCF-7 cells reveals no significant.

Supplementary Figure S1.

A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin

Chapter 08 The T Cell Receptor: Proteins and Genes

Sp1 Suppresses miR-3178 to Promote the Metastasis Invasion Cascade via Upregulation of TRIOBP Hui Wang, Kai Li, Yu Mei, Xuemei Huang, Zhenglin Li, Qingzhu.

A. D. B. C. - ΔNP63α - β-Actin IMEC - SUM MDA-MB IMEC

Supplemental Figure S1 a b

Supplemental Figure S2: G2 arrest in MCF7-shPBK1 stable cell line

Yang et al. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood. 2008;112(3):805–813. Blood Volume 114(14): October.

Cytotoxic therapy induces macrophage recruitment, as well as CSF1 and IL-34 mRNA expression. Cytotoxic therapy induces macrophage recruitment, as well.

Volume 10, Issue 5, Pages (November 2002)

Suppl. Figure 1 A B C D #### #### **** **** & && #### #### **** **** &

a b MCF-7 TR2 MCF-7 TR2 (Fold change) MTT Assay , (Fold change)

(A-B) Expression of dominant negative p73. (C) Knockdown of p73

B. MAb 9E1 reduces MMP-9 activity in MDA-MB-231 cells. A

In vitro effects of phthalate esters in human myometrial and leiomyoma cells and increased urinary level of phthalate metabolite in women with uterine.

Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors Klaus Bodner, M.D., Barbara Bodner-Adler, M.D., Oliver Kimberger,

a b AP-1 Sp1 Nuclear extract Competitor (100X) CDCA 50 µM + - M

Tomoyasu Hattori, Lukasz Stawski, Sashidhar S

Relative protein levels

MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α

Supplemental Figure 1A Pt Pt Pre-treatment

Supplemental Figure 1 a b c d.

Volume 113, Issue 2, Pages (April 2003)

Xiaolong Wei, Hai Xu, Donald Kufe Cancer Cell

Suppl. Fig. 2 A B Evaluation of FasL-induced apoptosis in BM-MSCs.

p27 Phosphorylation by Src Regulates Inhibition of Cyclin E-Cdk2

MUC1 Oncoprotein Stabilizes and Activates Estrogen Receptor α

Supplementary Figure S4

Reh cells, 24 hours c-Myc Ac-p53 b-actin

Volume 115, Issue 6, Pages (December 2003)

P. Ecimovic, D. Murray, P. Doran, J. McDonald, D. G. Lambert, D. J

20S proteasome activities

FIGURE 7-1 Block Diagram of Memory

Administration of an antiprogesterone up-regulates estrogen receptors in the endometrium of women using norplant™: a pilot study Anna F Glasier, M.D.,

C A B * * * * HCC1954 HCC1569 Supplementary-Figure S5 Tumor cells sc.

CYP1A1 knockdown increases cell death.

MW (kDa) 2 µg 0.5 µg Supplementary Figure S1. SDS-PAGE under reducing condition analysis (Coomassie brilliant blue staining) of.

CD151 effects on mammary cell morphology and adhesion.

* * * ** ** ** ** ** ** Fig. 1..

A B D C E F Supplementary Figure S4. Epping et al. IP: flag input IgG

Fig. 1. Clinical and histopathological appearances

Figure 4. MicroRNA (miR)-195 and miR-497 directly targets CD274

PELP1 regulates the expression and activities of MMPs in ER-negative cells. PELP1 regulates the expression and activities of MMPs in ER-negative cells.

Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.

Fig. 3. PTEN a target of miR-182-5p

I3C reduces the level of Cdc25A protein in breast cancer cells.

Presentation transcript:

Progesterone receptor Figure S1 A 231 SKBr3 Mcf-7 ZR75 B -130 kda Progesterone Receptor -100 kda -70 kda Estrogen Receptor Progesterone receptor Actin -55 kda Mcl-1 Actin -35 kda MCF-7

Figure S2 Fold increase Fold increase SKBr3 cells MDA-MB 231 cells

Fold increase in luciferase activity Figure S3 Fold increase in luciferase activity

Supplemental Figure S4 Input positive control for ChIP Negative control for ChIP No treatment E2 treatment, 6 hours No template control + -

Supplemental Figure S5 Figure 12